These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28209123)

  • 1. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.
    Derman BA; Macklis JN; Azeem MS; Sayidine S; Basu S; Batus M; Esmail F; Borgia JA; Bonomi P; Fidler MJ
    BMC Cancer; 2017 Feb; 17(1):141. PubMed ID: 28209123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Yao Y; Yuan D; Liu H; Gu X; Song Y
    Cancer Immunol Immunother; 2013 Mar; 62(3):471-9. PubMed ID: 22986452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
    Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
    Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
    Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
    Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
    Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
    Kiriu T; Yamamoto M; Nagano T; Hazama D; Sekiya R; Katsurada M; Tamura D; Tachihara M; Kobayashi K; Nishimura Y
    PLoS One; 2018; 13(2):e0193018. PubMed ID: 29447258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.
    Liu D; Jin J; Zhang L; Li L; Song J; Li W
    Cell Physiol Biochem; 2018; 46(4):1595-1605. PubMed ID: 29694985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
    Petrova MP; Eneva MI; Arabadjiev JI; Conev NV; Dimitrova EG; Koynov KD; Karanikolova TS; Valev SS; Gencheva RB; Zhbantov GA; Ivanova AI; Sarbianova II; Timcheva CV; Donev IS
    Biosci Trends; 2020 Mar; 14(1):48-55. PubMed ID: 32023563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neutrophil-to-lymphocyte ratio predicts the survival in patients with post-operative recurrence of non-small cell lung cancer].
    Wang X; Li K
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):298-302. PubMed ID: 24989918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
    Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
    Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
    Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.
    Suh KJ; Kim SH; Kim YJ; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
    Cancer Immunol Immunother; 2018 Mar; 67(3):459-470. PubMed ID: 29204702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
    Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.